SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as the crypto community discusses its recent price surge and potential as a privacy-focused alternative to Bitcoin. Community members are weighing in on potential price targets, the impact of institutional investment from figures like the Winklevoss twins, and its possible role in a shifting crypto landscape. Some traders believe ZEC has strong upside potential due to its privacy features, while others caution against the high volatility.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

PUPU CRYPTO is trending as the community rallies behind it, drawing comparisons to PEPE and DOGE while aiming for a $1 billion market cap. Built on the Solana blockchain, traders are highlighting its accessibility via Phantom Wallet and anticipating a potential breakout. The coin's momentum is being fueled by the broader excitement around meme coins.

VanEck ETF Trust - VanEck Oil Services ETF

VanEck Oil Services ETF

The VanEck Oil Services ETF ($OIH) is trending due to a mix of factors, including geopolitical tensions from Ukrainian attacks on Russian oil infrastructure and OPEC+ production decisions. Community discussions revolve around potential upside in the Oil Services sector, which has been lagging behind broader energy market gains, with some traders anticipating a significant move. Despite concerns over a possible oil supply surplus, some analysts and traders are pointing to robust demand and potential for sector outperformance.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending as the community discusses its potential for a run, while also grappling with concerns about scams and continuous crashes. The crypto market's overall health, government re-openings, and staking rewards are also hot topics among investors. Community members are closely watching for potential catalysts, including the LUNCVERSE Alpha launch and future exchange re-listings.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmax ($NMAX) is trending amid discussions around its relationship with political figures and potential market manipulation. Community members are actively debating the stock's valuation, recent earnings report, and its appeal as a potential acquisition target. Some traders are closely monitoring trading patterns, alleging possible short-selling tactics and coordinated efforts to suppress the stock price.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with community members actively discussing potential pumps and price movements, with some anticipating a significant ride while others express skepticism. Mentions of Elon Musk's potential influence and comparisons to other cryptocurrencies like ZEC are circulating. Overall, the conversation seems focused on short-term gains and market manipulation.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN is trending as the community anticipates it will follow the price action of ZEC, with some eyeing a potential move to $25. Chatter revolves around ZEN's potential to breakout and longer term, a Grayscale trust filing and migration to Base are adding to the bullish sentiment.

Century Aluminum Co. is a producer of aluminum and operates aluminum reduction facilities, or smelters, in the United States and Iceland. Its products include standard ingots, T-ingot, extrusion billet, horizontal direct chill ingot, molten, slab, and sow. The company was founded in 1995 and is headquartered in Chicago, IL.

Century Aluminum Co.

Century Aluminum is trending due to a mix of factors, including a recent earnings miss despite higher sales, and Glencore's plan to sell a significant stake in the company. The community is actively discussing technical indicators, potential trading strategies around the 50-day moving average, and the implications of the earnings miss on the stock's potential rally, in addition to a new power deal with Santee Cooper.

Polygon

Polygon ($MATIC) is trending amid mixed sentiment, with some community members expressing frustration over its recent performance while others point to potential catalysts like increased adoption and integration with Ethereum layer-2 solutions. Recent news around exchange upgrades to $POL and the project's developments in interoperability and real-world asset integration are being closely watched. Some traders are also speculating on potential short squeezes.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

PLCE is trending as investors discuss a potential short squeeze, with high short interest and a low float being key factors. The community is analyzing technical indicators and anticipating a significant price movement, particularly as the company shows signs of a turnaround and potential profitability. Some traders are also noting the impact of potential interest rate cuts and upcoming presentations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Scholar Rock Holding Stock Climbing Today?

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.read more...

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Scholar Rock Soar 26% Today?

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 

Equity

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee...

Scholar Rock (SRRK) to Release Earnings on Friday

Scholar Rock (NASDAQ:SRRK) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release of the...

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and...

A Canaccord analyst on Monday highlighted the risks associated with the U.S. Food and Drug Administration’s ‘Official Action Indicated’ designation on Catalent Indiana LLC, a third-party fill-finish facility.Novo Nordisk's (NVO) update that the FDA has classified Catalent Indiana LLC as "Official Action Indicated" raises the risk of further delay for Regeneron’s (REGN) Eylea HD prefilled syringes, as they are produced at the same site, the analyst noted. Catalent Indiana was acquired by Novo Nordisk (NVO) in December.Notably, Regeneron had <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">said</a> in August that the FDA extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions until the fourth quarter, owing to issues identified at the fill-finish facility.Regeneron is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-in-spotlight-after-fda-refuses-to-approve-muscular-atrophy-treatment/chDhUSIR35Z">refused</a> to approve Scholar Rock’s (SRRK) Apitegromab drug for the treatment of patients with spinal muscular atrophy over concerns identified during the inspection of Catalent Indiana's facility.Breaches at Catalent Indiana’s facility have been classified as "Official Action Indicated," Scholar Rock said in a statement. The serious designation means regulatory and/or administrative actions are recommended to resolve the concerns identified.Scholar Rock said that it continues to work closely with Novo and has requested a meeting with the FDA to discuss the next steps for resubmitting its Apitegromab drug application.While REGN shares traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> fell 12%. While retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, sentiment around SRRK rose from ‘neutral’ to ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:620/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_20_48_PM_png_df71d2ade1.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="620" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_21_27_PM_png_5e9ad0811c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>SRRK stock has dropped about 20% this year, while REGN lost 22%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-approves-changed-recommendations-for-use-of-abbvie-rinvoq/ch6SFlFR3lG">AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRRK News

SRRKScholar Rock Holding Corp